News

BMJ12d
B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial
Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN). We compared obinutuzumab, a humanised type II ...
BMJ6d
EULAR recommendations for the non-pharmacological core management of hip and knee osteoarthritis: 2023 update
Introduction Hip and knee osteoarthritis (OA) are increasingly common with a significant impact on individuals and society. Non-pharmacological treatments are considered essential to reduce pain and ...
BMJ8d
Synovial fibroblasts assume distinct functional identities and secrete R-spondin 2 in osteoarthritis
Correspondence to Dr Tristan Maerz, Department of Orthopaedic Surgery, University of Michigan, Ann Arbor, Michigan, USA; tmaerz{at}med.umich.edu Objectives Synovium is acutely affected following joint ...
BMJ9d
OP0016 EFFICACY AND SAFETY OF UPADACITINIB IN PATIENTS WITH ACTIVE NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS: A DOUBLE-BLIND, RANDOMIZED, PLACEBO ...
Background Janus kinase (JAK) inhibitors have been recognized as a potential therapeutic option in ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). 1 ...
BMJ8d
EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis
Correspondence to Dr Annette H M van der Helm-van Mil, Department of Rheumatology, Leiden University Medical Center, P.O. Box 9600, Leiden 2300 RC, The Netherlands; AvdHelm{at}lumc.nl Background ...
BMJ7d
Pathogenic antibody response to glucose-6-phosphate isomerase targets a modified epitope uniquely exposed on joint cartilage
Objectives To identify the arthritogenic B cell epitopes of glucose-6-phosphate isomerase (GPI) and their association with rheumatoid arthritis (RA). Methods IgG response towards a library of GPI ...
BMJ7d
In early rheumatoid arthritis, anticitrullinated peptide antibodies associate with low number of affected joints and rheumatoid factor associates with systemic inflammation
Objectives To investigate how individual rheumatoid arthritis (RA) autoantibodies associate with individual signs and symptoms at the time of RA diagnosis. Methods IgA, IgG, IgM rheumatoid factor (RF) ...
BMJ12d
EULAR recommendations for the management of systemic lupus erythematosus: 2023 update
Correspondence to Dr Dimitrios T Boumpas, Rheumatology and Clinical Immunology Unit, 4th Department of Internal Medicine, "Attikon" University Hospital, Joint Academic Rheumatology Program, National ...
BMJ12d
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis
4 Hospital de Santa Maria, Centro Hospitalar Universitario Lisboa Norte, Universidade de Lisboa, and Centro Académico deMedicina de Lisboa, Lisbon, Portugal 5 Oxford NIHR Biomedical Research Centre ...
BMJ12d
2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis
Objective To develop and validate revised classification criteria for granulomatosis with polyangiitis (GPA). Methods Patients with vasculitis or comparator diseases were recruited into an ...
BMJ2d
AB0163 PECULIARITIES OF INTERPRETATION OF THE PROCALCITONIN TEST IN RHEUMATOLOGICAL PATIENTS
Background: Assessment of serum procalcitonin (PCT) levels is of great interest in rheumatology in the diagnosis of infections, including infectious complications during active immunosuppressive ...
BMJ9d
Comparative analysis of SGLT-2 expression in renal vasculitis and lupus nephritis
Correspondence to Dr Björn Tampe, Department of Nephrology and Rheumatology, University Medical Center Göttingen, Göttingen 37075, Germany; bjoern.tampe{at}med.uni-goettingen.de In summary, this ...